LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Home・Список акций・Merck & Co Inc.

Merck & Co Inc.

Закрыт

СекторЗдравоохранение

111.24 -0.93

Купить Продать

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

111.13

Макс.

112.1

Ключевые показатели
By Trading Economics
Доход	-7.2B -4.2B
Продажи	-114M 16B
P/E Средняя по отрасли	31.507 49.8
Прибыль на акцию	-1.28
Дивидендная доходность	2.92
Рентабельность продаж	-26.053
Сотрудники	73,000
EBITDA	-6.2B -1.9B

Рекомендации
By TipRanks
Рекомендации	Покупка
Прогноз на 12 месяцев	+22.75% upside

Дивиденды
By Dow Jones
Дивидендная доходность Средняя по отрасли	2.92% 2.25%
Следующий отчет о доходах	4 авг. 2026 г.
Дата следующей выплаты дивидендов	7 июл. 2026 г.
Следующая эксдивидендная дата	15 июн. 2026 г.

Рыночная статистика
By TradingEconomics
Рыночная капитализация	7.1B 279B
Предыдущая цена открытия	112.17
Предыдущая цена закрытия	111.24

Новостные настроения

By Acuity

35%

65%

124 / 347 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Bearish Evidence

76.03 / 83.28 Поддержка и Сопротивление

Merck & Co Inc. График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

30 апр. 2026 г., 14:20 UTC

Отчет

Merck 1Q Sales Rise on Continued Keytruda Growth -- Update

30 апр. 2026 г., 10:45 UTC

Отчет

Merck 1Q Sales Rise on Continued Keytruda Growth

5 мая 2026 г., 18:12 UTC

Отчет

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5 мая 2026 г., 13:54 UTC

Отчет

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5 мая 2026 г., 12:48 UTC

Приобретения, слияния, поглощения

Merck Cites Costs Associated With Advancing TERN-701 and Financing >MRK

5 мая 2026 г., 12:48 UTC

Приобретения, слияния, поглощения

Merck: GAAP and Adj EPS Expected to Be Negatively Impacted by About 12c/Shr in 2026 >MRK

5 мая 2026 г., 12:47 UTC

Приобретения, слияния, поглощения

Merck: Transaction Expected to Be Accounted for as Asset Acquisition, Resulting in Chg of About $5.8 B, or $2.35/Shr, Included in 2Q and FY26 Results >MRK

5 мая 2026 г., 12:45 UTC

Приобретения, слияния, поглощения

Merck Completes Acquisition Of Terns Pharmaceuticals, Inc. >MRK TERN

1 мая 2026 г., 18:35 UTC

Отчет

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1 мая 2026 г., 14:53 UTC

Отчет

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

30 апр. 2026 г., 13:27 UTC

Отчет

Merck Stock Falls After Earnings. It's Working on Ways to Blunt Future Lost Keytruda Sales. -- Barrons.com

30 апр. 2026 г., 10:47 UTC

Отчет

Update: Merck Stock Rises on Earnings. These Problems Loom Larger Than Keytruda Patent Cliff. -- Barrons.com

30 апр. 2026 г., 10:30 UTC

Отчет

Merck: Also Anticipate EPS Will Be Negatively Affected by About 12c Over Remainder of 2026 Following Close of Terns Deal >MRK

30 апр. 2026 г., 10:30 UTC

Отчет

Merck Raises 2026 View To Adj EPS $5.04-Adj EPS $5.16 Vs Prior View $5-$5.15 >MRK

30 апр. 2026 г., 10:30 UTC

Отчет

Merck: 2026 Outlook Doesn't Reflect Any Impact From Proposed Acquisition of Terns Pharmaceuticals, Which Is Expected to Close in May and Result in One-Time Charge of About $2.35/Shr >MRK

30 апр. 2026 г., 10:30 UTC

Отчет

Merck: Sales Outlook Includes Positive Impact From Forex of About 1% at Mid-April 2026 Exchange Rates >MRK

30 апр. 2026 г., 10:30 UTC

Отчет

Merck: Adj EPS Outlook Also Reflects One-Time Charge of $3.62/Shr for Acquisition of Cidara >MRK

30 апр. 2026 г., 10:30 UTC

Отчет

Merck: Adj EPS Outlook Includes Positive Impact From Forex of About 10c/Shr at Mid-April 2026 Exchange Rates >MRK

30 апр. 2026 г., 10:30 UTC

Отчет

Merck Narrows 2026 View To Sales $65.8B-$67B Vs Prior View $65.5B-$67B >MRK

30 апр. 2026 г., 10:30 UTC

Отчет

Merck: Latest 1Q Includes Charge of $3.62/Share for the Acquisition of Cidara >MRK

30 апр. 2026 г., 10:30 UTC

Отчет

Merck: 1Q Gardasil/Gardasil 9 Sales Also Reflect Lower Sales in U.S. Primarily Due to Unfavorable Public-Sector Purchasing Patterns, Partially Offset by Higher Net Pricing >MRK

30 апр. 2026 г., 10:30 UTC

Отчет

Merck 1Q Gardasil/Gardasil 9 Sales Down 19% >MRK

30 апр. 2026 г., 10:30 UTC

Отчет

Merck: Lower 1Q Januvia/Janumet Sales Due to Lower Demand and Net Pricing in U.S., Lower Demand in China and Most Other International Markets Due to Generic Competition >MRK

30 апр. 2026 г., 10:30 UTC

Отчет

Merck: Pleased With Progress and Excited for What's Ahead, as We Enter Particularly Robust Period of Phase 3 Data Readouts and Deliver on Promise of Our Pipeline for Patients >MRK

30 апр. 2026 г., 10:30 UTC

Отчет

Merck 1Q Winrevair Sales $525M, Up 88%, Reflecting Continued Uptake in U.S. and Early Launch Uptake in Certain Intl Mkts, Especially Japan and Europe >MRK

30 апр. 2026 г., 10:30 UTC

Отчет

Merck: 1Q Animal Health Sales Growth Attributable to Performance in Both Livestock and Companion Animal Product Portfolios >MRK

30 апр. 2026 г., 10:30 UTC

Отчет

Merck: Lower 1Q Gardasil/Gardasil 9 Sales Primarily Due to Lower Demand in China as Well as Lower Sales in Japan Following National Catch-Up Immunization Program >MRK

30 апр. 2026 г., 10:30 UTC

Отчет

Merck 1Q Pharmaceutical Sales Up 5% >MRK

30 апр. 2026 г., 10:30 UTC

Отчет

Merck 1Q Animal Health Sales Up 13% >MRK

30 апр. 2026 г., 10:30 UTC

Отчет

Merck 1Q Sales $16.29B >MRK

Сравнение c конкурентами

Изменение цены

Merck & Co Inc. Прогноз

Целевая цена

By TipRanks

22.75% рост

Прогноз на 12 месяцев

Средняя 136.72 USD 22.75%

Максимум 179 USD

Минимум 112 USD

Основано на мнении 20 аналитиков Wall Street, спрогнозировавших целевые цены для Merck & Co Inc. на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

20 ratings

Покупка

Удержание

Продажа

Основано на мнении 20 аналитиков, присваивавших рейтинги акциям Merck & Co Inc. – Данные за последние 3 месяца.

Техническая оценка

By Trading Central

76.03 / 83.28Поддержка и Сопротивление

Recent bearish events outweigh bullish events.

All events are bearish.

Настроения

By Acuity

124 / 347Рейтинг в Здравоохранение

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

О компании Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.